Cargando…
Phytate Decreases Formation of Advanced Glycation End-Products in Patients with Type II Diabetes: Randomized Crossover Trial
Myo-inositol hexaphosphate (phytate; IP6) is a natural compound that is abundant in cereals, legumes, and nuts and it has the ability to chelate metal cations. The binding of IP6 to transition metals suggests that it could be used for the treatment of metal-catalyzed protein glycation, which appears...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018557/ https://www.ncbi.nlm.nih.gov/pubmed/29941991 http://dx.doi.org/10.1038/s41598-018-27853-9 |
_version_ | 1783334978154659840 |
---|---|
author | Sanchis, Pilar Rivera, Rosmeri Berga, Francisco Fortuny, Regina Adrover, Miquel Costa-Bauza, Antonia Grases, Felix Masmiquel, Luis |
author_facet | Sanchis, Pilar Rivera, Rosmeri Berga, Francisco Fortuny, Regina Adrover, Miquel Costa-Bauza, Antonia Grases, Felix Masmiquel, Luis |
author_sort | Sanchis, Pilar |
collection | PubMed |
description | Myo-inositol hexaphosphate (phytate; IP6) is a natural compound that is abundant in cereals, legumes, and nuts and it has the ability to chelate metal cations. The binding of IP6 to transition metals suggests that it could be used for the treatment of metal-catalyzed protein glycation, which appears to trigger diabetes-related diseases. Our in vitro studies showed that IP6 reduced the formation of Fe(3+)-catalyzed advanced glycation end-products (AGEs). This led us to perform a randomized cross-over trial to investigate the impact of the daily consumption IP6 on protein glycation in patients with type 2 diabetes mellitus (T2DM; n = 33). Thus, we measured AGEs, glycated hemoglobin (HbA1c), several vascular risk factors, and urinary IP6 at baseline and at the end of the intervention period. Patients who consumed IP6 supplements for 3 months had lower levels of circulating AGEs and HbA1c than those who did not consume IP6. This is the first report to show that consumption of IP6 inhibits protein glycation in patients with T2DM. Considering that AGEs contribute to microvascular and macrovascular complications in T2DM, our data indicates that dietary supplementation with IP6 should be considered as a therapy to prevent the formation of AGEs and therefore, the development of diabetes-related diseases in patients with T2DM. |
format | Online Article Text |
id | pubmed-6018557 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-60185572018-07-06 Phytate Decreases Formation of Advanced Glycation End-Products in Patients with Type II Diabetes: Randomized Crossover Trial Sanchis, Pilar Rivera, Rosmeri Berga, Francisco Fortuny, Regina Adrover, Miquel Costa-Bauza, Antonia Grases, Felix Masmiquel, Luis Sci Rep Article Myo-inositol hexaphosphate (phytate; IP6) is a natural compound that is abundant in cereals, legumes, and nuts and it has the ability to chelate metal cations. The binding of IP6 to transition metals suggests that it could be used for the treatment of metal-catalyzed protein glycation, which appears to trigger diabetes-related diseases. Our in vitro studies showed that IP6 reduced the formation of Fe(3+)-catalyzed advanced glycation end-products (AGEs). This led us to perform a randomized cross-over trial to investigate the impact of the daily consumption IP6 on protein glycation in patients with type 2 diabetes mellitus (T2DM; n = 33). Thus, we measured AGEs, glycated hemoglobin (HbA1c), several vascular risk factors, and urinary IP6 at baseline and at the end of the intervention period. Patients who consumed IP6 supplements for 3 months had lower levels of circulating AGEs and HbA1c than those who did not consume IP6. This is the first report to show that consumption of IP6 inhibits protein glycation in patients with T2DM. Considering that AGEs contribute to microvascular and macrovascular complications in T2DM, our data indicates that dietary supplementation with IP6 should be considered as a therapy to prevent the formation of AGEs and therefore, the development of diabetes-related diseases in patients with T2DM. Nature Publishing Group UK 2018-06-25 /pmc/articles/PMC6018557/ /pubmed/29941991 http://dx.doi.org/10.1038/s41598-018-27853-9 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Sanchis, Pilar Rivera, Rosmeri Berga, Francisco Fortuny, Regina Adrover, Miquel Costa-Bauza, Antonia Grases, Felix Masmiquel, Luis Phytate Decreases Formation of Advanced Glycation End-Products in Patients with Type II Diabetes: Randomized Crossover Trial |
title | Phytate Decreases Formation of Advanced Glycation End-Products in Patients with Type II Diabetes: Randomized Crossover Trial |
title_full | Phytate Decreases Formation of Advanced Glycation End-Products in Patients with Type II Diabetes: Randomized Crossover Trial |
title_fullStr | Phytate Decreases Formation of Advanced Glycation End-Products in Patients with Type II Diabetes: Randomized Crossover Trial |
title_full_unstemmed | Phytate Decreases Formation of Advanced Glycation End-Products in Patients with Type II Diabetes: Randomized Crossover Trial |
title_short | Phytate Decreases Formation of Advanced Glycation End-Products in Patients with Type II Diabetes: Randomized Crossover Trial |
title_sort | phytate decreases formation of advanced glycation end-products in patients with type ii diabetes: randomized crossover trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018557/ https://www.ncbi.nlm.nih.gov/pubmed/29941991 http://dx.doi.org/10.1038/s41598-018-27853-9 |
work_keys_str_mv | AT sanchispilar phytatedecreasesformationofadvancedglycationendproductsinpatientswithtypeiidiabetesrandomizedcrossovertrial AT riverarosmeri phytatedecreasesformationofadvancedglycationendproductsinpatientswithtypeiidiabetesrandomizedcrossovertrial AT bergafrancisco phytatedecreasesformationofadvancedglycationendproductsinpatientswithtypeiidiabetesrandomizedcrossovertrial AT fortunyregina phytatedecreasesformationofadvancedglycationendproductsinpatientswithtypeiidiabetesrandomizedcrossovertrial AT adrovermiquel phytatedecreasesformationofadvancedglycationendproductsinpatientswithtypeiidiabetesrandomizedcrossovertrial AT costabauzaantonia phytatedecreasesformationofadvancedglycationendproductsinpatientswithtypeiidiabetesrandomizedcrossovertrial AT grasesfelix phytatedecreasesformationofadvancedglycationendproductsinpatientswithtypeiidiabetesrandomizedcrossovertrial AT masmiquelluis phytatedecreasesformationofadvancedglycationendproductsinpatientswithtypeiidiabetesrandomizedcrossovertrial |